Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 18/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621556 | 0.93 | PTGER1 (0.59) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5619462 | 0.92 | PTGER1 (0.63) | PTGER1CYP2C9 | |
| SCHEMBL5620289 | 0.91 | PTGER1 (0.64) | PTGER1CYP2C9 | |
| SCHEMBL14499125 | 0.91 | PTGER1 (0.65) | PTGER1CYP2C9 | |
| SCHEMBL5620834 | 0.89 | PTGER1 (0.77) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5621256 | 0.88 | PTGER1 (0.69) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5621099 | 0.88 | PTGER1 (0.67) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL14499122 | 0.88 | PTGER1 (0.64) | PTGER1CYP2C9TBXA2R | |
| SCHEMBL5621668 | 0.88 | PTGER1 (0.66) | PTGER1CYP2C9 | |
| SCHEMBL6141665 | 0.88 | PTGER1 (0.52) | PTGER1CYP2C9TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | PTGER1 323/4885CYP2C9 1/4885CCR5 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.